Date of inclusion: 10 March 2021
Share price on inclusion: $1.255
Date of exclusion: 25 August 2021
Share price on exclusion: $2.24
Neuren has performed well since we included it in Marc and Stuart’s Top Picks list on 10 March 2021, rising 78.5%. We like the potential of this company to revolutionise the treatment of rare neurological disorders with its trofinenide drug. The Phase 2 data in Rett Ryndrome looked good and the company secured Acadia Pharmaceuticals (Nasdaq: ACAD) ...